John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

EditorialPublication Exclusive

Cancer progress reports: The gap between discovery and delivery

HemOnc Today, October 10, 2014
John Sweetenham, MD
In the past year or so, there have been several notable, “big-picture” reports about the state of cancer research, care and survival in…
EditorialPublication Exclusive

The changing face of our major meetings: Evolution or revolution?

HemOnc Today, September 10, 2014
John Sweetenham, MD, PhD
One morning in late July, I was poised over my laptop at exactly 9 a.m. Mountain time, ready for the ASH Annual Meeting and Exposition registration…

From research funding to drug pricing: 12 questions to ask your political candidates

HemOnc Today, July 10, 2014
Derek Raghavan, MD, PhD; John Sweetenham, MD
This is the first edition of HemOnc Today with the two of us at the helm as chief medical editors, and we wish to signal the event by providing a…

Response-adapted therapy of lymphoma: Real progress or really confusing?

HemOnc Today, August 10, 2014
John Sweetenham, MD
In the past few years, the lymphoma literature has featured an increasing number of studies — some well-designed, most not so — designed…
EditorialPublication Exclusive

Better cancer care: My ‘one thing’ to learn more about this week

HemOnc Today, April 10, 2015
John Sweetenham, MD
In the past few weeks, I have been fortunate enough to be involved in several strategic retreats. These retreats have involved different groups of…